Aastrom Biosciences, Inc., a clinical-stage biotechnology company, focuses on the development of cell therapies for use in the treatment of severe chronic ischemic cardiovascular diseases. The company is developing a manufacturing technology platform, the Aastrom Replicell System, which enables the expansion of a various cell types, including the production of multicellular therapies expanded from an adult patients own bone marrow that can be delivered directly to damaged tissues. Its lead product candidate include ixmyelocel-T, to treat patients with severe chronic ischemic cardiovascular diseases, such as advanced heart failure due to dilated cardiomyopathy, the third leading cause of heart failure, and critical limb ischemia. The company was founded in 1989 and is headquartered in Ann Arbor, Michigan.
April 10, 2024
RegMed Investors (RMi) Closing Bell: the cell and gene therapy sector got chewed-up, bloods everywhere
April 8, 2024
RegMed Investors (RMi) Closing Bell: what’s moving the sector?
April 5, 2024
RegMed Investors (RMi) Closing Bell: economic circumstances drove a 5 session/weekly downside
April 5, 2024
RegMed Investors’ (RMi) pre-open: The sector remains highly sensitive in any indication
April 4, 2024
RegMed Investors (RMi) Closing Bell: economics undermine sector’s share pricing before jobs report
April 4, 2024
RegMed Investors’ (RMi) pre-open: missing the beat or beating the miss?
April 2, 2024
RegMed Investors (RMi) Closing Bell: weakness is more of a wipe-out
April 2, 2024
RegMed Investors (RMi) - Q4/23 & FY23 Cell and Gene Therapy Earnings Scorecard Results
April 1, 2024
RegMed Investors (RMi) Closing Bell: An early share pricing eclipse in first session of April?
35 companies, 1 interpreter!
Insight, foresight and recommendation
Vericel (VCEL) – Opened 1/2/18 at $5.90, saw a high of $7.30; started February at $8.15 slipping with a low of $6.60 and started March at $8.05 jumping to $11.35 on $3/6 after announcing a $300 K net incomeand a per share value of +$0.01. Further thoughts rflect strong use of an ATM and at this "peak" - a financing "could" ensue ...
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors